NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Globe Newswire•04/11/2026•07:30 ET
0
Key Highlights
- ➤EC approved Ubeslo and Evlarco, marking obicetrapib’s first worldwide regulatory approval
- ➤PREVAIL interim analysis planned for 4Q2026; results expected in 1Q2027
- ➤SPINOZA Phase 2b trial initiated in approximately 400 preclinical Alzheimer’s patients
- ➤Cash, equivalents and marketable securities totaled $643.1 million at September 30, 2026
- ➤Q3 revenue rose to $19.2 million from $0.3 million on Menarini milestones
Expert Statements
Michael Davidson, Chief Executive Officer of NewAmsterdam Pharma
“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027. With PREVAIL, the first cardiovascular outcomes trial evaluating a CETP inhibitor in more than a decade, advancing toward its next major inflection point and top-line data from our Phase 3 RUBENS trial expected around year-end, we look forward to these upcoming readouts as we continue to build the body of evidence supporting obicetrapib across cardiovascular disease and other areas of significant unmet need.”
– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide –
– Initiated SPINOZA Phase 2b trial evaluating obicetrapib in preclinical Alzheimer’s disease –
Get started
Create a free account to read the full story.